Key result
Soluble POSTN demonstrated superior diagnostic accuracy for distinguishing healthy controls from locoregional breast cancer compared to CA153.
Why the study?
Reliable biomarkers for early diagnosis and metastasis prediction are essential to improve breast cancer prognosis, prompting evaluation of serum periostin complementing CA153 and CEA.
Does serum POSTN complement CA153 and CEA in diagnosing breast cancer and predicting metastasis?
Case-Control (n=242)
No
Does serum POSTN complement CA153 and CEA in diagnosing breast cancer and predicting metastasis?
Soluble POSTN is a promising biomarker that complements CA153 and CEA for the diagnosis and metastasis prediction of breast cancer.
Answers are grounded in this paper and cite their sources.
Serum POSTN may complement CA153 and CEA for BCa diagnosis and metastasis prediction; leaves open routine adoption pending prospective validation.
Background Breast cancer (BCa) is the leading cause of cancer deaths among women. Reliable biomarkers for early diagnosis and metastasis prediction are essential to improve the prognosis of BCa. This study aimed to evaluate serum periostin (POSTN) as a novel biomarker complementing CA153 (carbohydrate antigen 153) and CEA (carcinoembryonic antigen) for BCa diagnosis and metastasis prediction. Methods To assess the potential of soluble POSTN as a circulating biomarker, 242 participants, including 173 patients with different stages of BCa and 69 healthy individuals, were enrolled in this study. Soluble POSTN, together with CA153 and CEA, were determined in serum by enzyme linked immunosorbent assay (ELISA) or electrochemiluminescence immunoassays. Results Serum POSTN levels in locoregional BCa patients were significantly higher than that in healthy controls. Receiver operating curve (ROC) analysis revealed that, to distinguish health controls from locoregional BCa, POSTN was observed with the highest AUC (area under curve) (AUCPOSTN = 0.72 [0.65 – 0.79], AUCCA153 = 0.57 [0.49 – 0.64], AUCCEA = 0.62 [0.55 – 0.69]), and both CA153 and CEA were observed with significantly improved AUCs by combination with POSTN (AUCPOSTN + CA153 = 0.74 [0.67 – 0.80], P < 0.001; AUCPOSTN + CEA = 0.77 [0.70 – 0.82], P < 0.001). Moreover, the performances of the POSTN were comparable with that of CA153 in predicting distant metastasis of BCa (AUCPOSTN = 0.78 [0.71 – 0.84], AUCCA153 = 0.82 [0.76 – 0.88]). Kaplan–Meier analysis indicated that elevated serum POSTN was associated with poor overall survival and progression-free survival. Conclusions This study suggested that soluble POSTN is a promising potential biomarker for diagnosis and metastasis prediction of BCa.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2022) conducted a case-control in Breast cancer (n=242). Soluble POSTN vs. CA153 and CEA was evaluated on Distinguishing healthy controls from locoregional breast cancer (AUC 0.72, 95% CI 0.65-0.79, p=<0.01). Soluble POSTN demonstrated superior diagnostic accuracy for distinguishing healthy controls from locoregional breast cancer compared to CA153.
Synapse has enriched 10 related papers. Consider them for comparative context: